Hikma Pharmaceuticals PLC provided group earnings guidance for the year 2024. For the year, the group expects revenue to grow in the range of 4% to 6%. Core operating profit to be in the range of $660 million to $700 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,924 GBX | -0.31% | +5.83% | +7.55% |
Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.55% | 5.35B | |
+34.00% | 704B | |
+29.29% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+13.79% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals PLC Provides Group Earnings Guidance for the Year 2024